Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing.

Authors:
Inês Nogueira Costa Joana Reis Sara Meireles Maria João Ribeiro Miguel Barbosa Isabel Augusto

Eur J Case Rep Intern Med 2022 24;9(5):003331. Epub 2022 May 24.

Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal.

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alterations in order to apply targeted therapies. Increasing evidence suggests that the PARP inhibitor olaparib could have a significant synthetic lethal effect in prostate cancer with homologous recombination defects, such as BRCA1/2 mutations. It is not yet known if, under these circumstances, platinum-based chemotherapy induces higher response rates in prostate cancer. We present the case of a patient with BRCA2-mutated metastatic castration-resistant prostate cancer whose treatment sequence included carboplatin and olaparib.

Learning Points: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease despite significant progress in treatment.The BRCA2 mutation is associated with worse survival and so timely genetic screening is important.Studies are needed to identify the best therapeutic sequencing strategy for mCRPC harbouring homologous recombination repair defects, which includes PARP inhibitors and platinum.

Download full-text PDF

 Source
http://dx.doi.org/10.12890/2022_003331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239024PMC
May 2022

Publication Analysis

Top Keywords

prostate cancer
24
metastatic castration-resistant
12
castration-resistant prostate
12
inhibitors platinum
8
homologous recombination
8
brca2 mutation
8
parp inhibitors
8
prostate
6
cancer
6
chemotherapy induces
4
induces higher
4
higher response
4
response rates
4
case patient
4
rates prostate
4
cancer case
4
circumstances platinum-based
4
patient brca2-mutated
4
brca2-mutated metastatic
4
cancer treatment
4

Keyword Occurance

Similar Publications

Prostate cancer: case finding scheme is unapproved "screening by stealth," GPs claim.

Authors:
Elisabeth Mahase

BMJ 2022 Aug 12;378:o2015. Epub 2022 Aug 12.

The BMJ.

View Article and Full-Text PDF
August 2022
Similar Publications

18F-FDG PET/CT in Urethral Metastases From Bladder Cancer.

Authors:
Ediz Beyhan Sevim Baykal Koca Uğur Yücetaş Tevfik Fikret Çermik Nurhan Ergül

Clin Nucl Med 2022 Aug 4. Epub 2022 Aug 4.

From the Clinic of Nuclear Medicine.

Abstract: Urethral metastasis of bladder cancer after surgery is rare. We present a 63-year-old man who had surgery for invasive bladder carcinoma and prostate adenocarcinoma 4 years ago and referred for urethral hemorrhage. 18F-FDG PET/CT was performed for restaging and showed intense linear 18F-FDG activity in the proximal urethra. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

68Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.

Authors:
Yizhen Pang Tinghua Meng Weizhi Xu Qihang Shang Haojun Chen

Clin Nucl Med 2022 Aug 4. Epub 2022 Aug 4.

From the Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Abstract: 68Ga-labeled PET tracer targeting PSMA is a promising diagnostic approach for staging and restating of prostate cancer (PCa), but cases with clinically relevant PCa and false-negative PSMA PET/CT have been reported. In this case, we reported 68Ga-PSMA, 18F-FDG, and 68Ga-FAPI PET/CT findings in a 65-year-old man with de novo metastatic PCa. 68Ga-FAPI PET/CT detected non-PSMA/FDG-avid primary PCa, consisting with multiparametric MRI findings. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

18F-Fluciclovine PET Detected Early Tumor Recurrence in Prostatectomy Bed With Low PSA of 0.3 ng/mL But Negative on 18F-PSMA PET Scan.

Authors:
Trinh T Nguyen Priya R Bhosale Yang Lu

Clin Nucl Med 2022 Aug 4. Epub 2022 Aug 4.

From the Departments of Nuclear Medicine.

Abstract: A 58-year-old man with metastatic prostate cancer was treated with prostatectomy, radiation therapy to bone metastasis, and androgen deprivation therapy plus abiraterone. He had posttreatment nadir PSA of 0.1 ng/mL. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Comparison of Internal Dosimetry of 18F-PSMA-1007 and 68Ga-PSMA-11-HBED-CC.

Authors:
Priya Sharma Ankit Watts Harmandeep Singh

Clin Nucl Med 2022 Aug 4. Epub 2022 Aug 4.

From the Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Background: Prostate cancer (PCa) is the most common cancer in men worldwide. Targeting prostate-specific membrane antigen (PSMA) using radiopharmaceuticals has shown promising results for PCa imaging as well as theranostics. 68Ga-based PSMA imaging is limited by production of small quantities by generator, and it has led to quest for cyclotron produced 18F-based PSMA ligands. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}